Tubulin is an obligate folding substrate of TRiC/CCT,9 and targeting the β‐tubulin/CCT2 interaction promotes cancer cell apoptosis112; thus, the combination of CCT and microtubule‐targeting agents (including doxorubicin, paclitaxel, vincristine, vinblastine and colchicine) can overcome chemoresistance to achieve clinical success. The gene discussed is CCT2; the disease is cancer.